JP2017536340A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536340A5
JP2017536340A5 JP2017518446A JP2017518446A JP2017536340A5 JP 2017536340 A5 JP2017536340 A5 JP 2017536340A5 JP 2017518446 A JP2017518446 A JP 2017518446A JP 2017518446 A JP2017518446 A JP 2017518446A JP 2017536340 A5 JP2017536340 A5 JP 2017536340A5
Authority
JP
Japan
Prior art keywords
cancer
composition
metastatic
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518446A
Other languages
English (en)
Japanese (ja)
Other versions
JP6678941B2 (ja
JP2017536340A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/054011 external-priority patent/WO2016057398A1/en
Publication of JP2017536340A publication Critical patent/JP2017536340A/ja
Publication of JP2017536340A5 publication Critical patent/JP2017536340A5/ja
Application granted granted Critical
Publication of JP6678941B2 publication Critical patent/JP6678941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518446A 2014-10-07 2015-10-05 抗体−薬物コンジュゲートのネオアジュバント使用 Active JP6678941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060858P 2014-10-07 2014-10-07
US62/060,858 2014-10-07
PCT/US2015/054011 WO2016057398A1 (en) 2014-10-07 2015-10-05 Neoadjuvant use of antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035068A Division JP7144121B2 (ja) 2014-10-07 2020-03-02 抗体－薬物コンジュゲートのネオアジュバント使用

Publications (3)

Publication Number Publication Date
JP2017536340A JP2017536340A (ja) 2017-12-07
JP2017536340A5 true JP2017536340A5 (cg-RX-API-DMAC7.html) 2018-10-18
JP6678941B2 JP6678941B2 (ja) 2020-04-15

Family

ID=55632016

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017518446A Active JP6678941B2 (ja) 2014-10-07 2015-10-05 抗体−薬物コンジュゲートのネオアジュバント使用
JP2020035068A Active JP7144121B2 (ja) 2014-10-07 2020-03-02 抗体－薬物コンジュゲートのネオアジュバント使用
JP2022145199A Pending JP2022184938A (ja) 2014-10-07 2022-09-13 抗体－薬物コンジュゲートのネオアジュバント使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020035068A Active JP7144121B2 (ja) 2014-10-07 2020-03-02 抗体－薬物コンジュゲートのネオアジュバント使用
JP2022145199A Pending JP2022184938A (ja) 2014-10-07 2022-09-13 抗体－薬物コンジュゲートのネオアジュバント使用

Country Status (11)

Country Link
US (3) US20160095939A1 (cg-RX-API-DMAC7.html)
EP (2) EP3204018B1 (cg-RX-API-DMAC7.html)
JP (3) JP6678941B2 (cg-RX-API-DMAC7.html)
CN (2) CN117138060A (cg-RX-API-DMAC7.html)
AU (2) AU2015328370B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961774C (cg-RX-API-DMAC7.html)
ES (1) ES2892525T3 (cg-RX-API-DMAC7.html)
PL (1) PL3204018T3 (cg-RX-API-DMAC7.html)
PT (1) PT3204018T (cg-RX-API-DMAC7.html)
SI (1) SI3204018T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016057398A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2017180565A1 (en) * 2016-04-14 2017-10-19 Immunomedics, Inc. Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers
CA3059593A1 (en) * 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
CA3066054A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
WO2019079549A1 (en) * 2017-10-18 2019-04-25 Forty Seven, Inc. TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1
AU2018351006B2 (en) 2017-10-18 2024-08-29 Forty Seven, LLC Anti-CD47 agent-based ovarian cancer therapy
CN111093703A (zh) * 2017-11-17 2020-05-01 江苏恒瑞医药股份有限公司 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途
CA3081925A1 (en) * 2017-11-18 2019-05-23 Nzola DE MAGALHAES Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
EP3498308B1 (en) 2017-12-13 2024-11-27 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
PE20211305A1 (es) * 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
JP7455802B2 (ja) * 2018-07-13 2024-03-26 メモリアル スローン－ケタリング キャンサー センター Ｄｏｔａプレターゲット放射免疫療法のためのｎ－アセチルガラクトサミノデンドロン除去剤
CN110812485A (zh) * 2018-08-10 2020-02-21 江苏恒瑞医药股份有限公司 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途
EP3858386A4 (en) * 2018-09-26 2022-10-12 Jiangsu Hengrui Medicine Co., Ltd. LIGAND-DRUG CONJUGATE OF AN EXATECAN ANALOG, METHOD FOR PREPARATION AND THEIR USE
IL284623B2 (en) * 2019-01-07 2025-04-01 Astellas Pharma Inc A conjugate containing a ligand, a spacer, a peptide linker, and a biomolecule
CR20220058A (es) 2019-07-10 2022-07-19 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CA3177279A1 (en) * 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
TW202308706A (zh) * 2021-04-21 2023-03-01 日商日本醫事物理股份有限公司 放射性抗腫瘤劑
WO2022271771A2 (en) * 2021-06-22 2022-12-29 The General Hospital Corporation Therapeutic targeting of cadherin 11 in cancer
WO2023008982A1 (ko) * 2021-07-30 2023-02-02 서울대학교산학협력단 항 cd154 항체 및 이의 용도
WO2023032994A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
WO2023032995A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
JPWO2023032996A1 (cg-RX-API-DMAC7.html) 2021-08-31 2023-03-09
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
WO2023150899A1 (en) * 2022-02-08 2023-08-17 Canwell Biotech Limited Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
WO2023204547A1 (ko) * 2022-04-18 2023-10-26 주식회사 노벨티노빌리티 슈도모나스 외독소 a를 포함하는 c-kit 표적 면역접합체
CN114859050A (zh) * 2022-05-30 2022-08-05 复旦大学附属肿瘤医院 三阴性乳腺癌免疫治疗疗效预测标志物ccl19的检测方法
TW202421668A (zh) * 2022-11-25 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 抗liv-1抗體、其藥物偶聯物及其醫藥用途
CN120380327A (zh) 2022-12-26 2025-07-25 富士胶片株式会社 荧光强度增强剂、经荧光标记的靶标生物物质的荧光强度增强方法及荧光检测用试剂盒
JPWO2024181455A1 (cg-RX-API-DMAC7.html) 2023-02-27 2024-09-06
JPWO2024181454A1 (cg-RX-API-DMAC7.html) 2023-02-27 2024-09-06
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025206085A1 (ja) * 2024-03-28 2025-10-02 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6511665B1 (en) 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US6432402B1 (en) 1989-05-25 2002-08-13 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
DE69028684T2 (de) 1989-06-02 1997-05-22 The Johns Hopkins University School Of Medicine, Baltimore, Md. Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
IL97459A0 (en) 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
US5196522A (en) 1990-11-01 1993-03-23 Board Of Regents, The University Of Texas System Anthracycline analogues bearing latent alkylating substituents
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1993015405A1 (en) 1992-01-29 1993-08-05 Sci-Clone, Inc. Carcinoma associated antigen (sk1) monoclonal antibodies against sk1, methods of producing these antibodies and use therfor
CA2131692A1 (en) 1992-03-09 1993-09-16 Sybille Muller An anti-idiotypic antibody and its use in diagnosis and therapy in hiv-related disease
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
CA2132091C (en) 1992-04-03 2008-09-16 Kyung J. Kim Antibodies to alphavbeta3 integrin
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
WO1993021940A1 (en) 1992-05-06 1993-11-11 Immunomedics, Inc. Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
WO1994026297A1 (en) 1993-05-17 1994-11-24 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
DE69434812D1 (de) 1993-05-28 2006-09-14 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
WO1995007102A1 (en) 1993-09-09 1995-03-16 Duke University A method of promoting cellular function
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
WO1995014040A1 (en) 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US6432404B1 (en) 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
US5922572A (en) 1994-01-25 1999-07-13 Human Genome Sciences, Inc. Polynucleotides encoding haemopoietic maturation factor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6100389A (en) 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6709653B1 (en) 1994-09-16 2004-03-23 Human Genome Sciences, Inc. Antibodies specific for human inositol monophosphatase H1
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5750370A (en) 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
US6538121B1 (en) 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US5786204A (en) 1995-01-20 1998-07-28 Human Genome Sciences, Inc. Human prostatic specific reductase
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6605441B1 (en) 1995-06-05 2003-08-12 Human Genome Sciences, Inc. Antibodies against fibroblast growth factor 11
AU6223296A (en) 1995-06-07 1996-12-30 Novartis Ag Methods for obtaining compositions enriched for hematopoieti c stem cells and antibodies for use therein
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5945309A (en) 1996-03-19 1999-08-31 Human Genome Sciences, Inc. Cytostatin III nucleic acids encoding
WO1997034632A1 (en) 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
ATE303161T1 (de) 1996-03-20 2005-09-15 Immunomedics Inc Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
FR2746398B1 (fr) 1996-03-21 1998-04-30 Bio Merieux Anticorps specifique de staphylococcus aureaus, et utilisations
US6174992B1 (en) 1997-03-21 2001-01-16 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor I, II and III
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US6110463A (en) 1996-03-29 2000-08-29 North Carolina State University Anti-Cryptosporidium parvum preparations
US6066617A (en) 1996-04-03 2000-05-23 Human Genome Sciences, Inc. Human cystatin F
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
AU4031997A (en) 1996-09-03 1998-03-26 Kaneka Corporation Method for inducing immunosuppressive cells and culturing device to be used herefor
DE69731977T2 (de) 1996-10-09 2005-12-08 Canterbury Health Ltd. Spezifische antikörper für dendritische zellen
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6395276B1 (en) 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells
DE69719529T2 (de) 1996-10-17 2003-12-11 Immunomedics, Inc. Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6043348A (en) 1996-11-13 2000-03-28 Lawman; Michael J. P. Antibody recognizing a small subset of human hematopoietic cells
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0988385A2 (en) 1997-01-21 2000-03-29 Human Genome Sciences Tace-like and matrilysin-like polypeptides
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
ATE427966T1 (de) 1997-02-11 2009-04-15 Immunomedics Inc Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
EP0977991A4 (en) 1997-03-03 2004-12-15 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES FOR HUMAN CD6
US6919433B2 (en) 1997-03-14 2005-07-19 Human Genome Sciences, Inc. Antibodies to protein HPMBQ91
US6951924B2 (en) 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6284474B1 (en) 1998-04-23 2001-09-04 The Regents Of The University Of California Detection and diagnosis of conditions associated with lung injury
US6372217B1 (en) 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
US6545130B2 (en) 1997-06-04 2003-04-08 Albert Einstein College Of Medicine Of Yeshiva University Monoclonal antibodies to mycobacterium tuberculosis and a modified ELISA assay
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
ES2306480T3 (es) 1997-09-18 2008-11-01 Genentech, Inc. Polipeptido dcr3, un homologo de tnfr.
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6200765B1 (en) 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
EP1079862B1 (en) 1998-05-20 2010-07-07 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
IL139700A (en) 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6528269B1 (en) 1998-06-22 2003-03-04 Case Western Reserve University Immunological agents specific for prion protein (PRP)
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
JP4113670B2 (ja) 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
EP1127170A4 (en) 1998-11-05 2005-04-27 Univ Leland Stanford Junior HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN
ES2259247T3 (es) 1998-12-21 2006-09-16 Ludwig Institute For Cancer Research Anticuerpos frente a vegf-d truncado y sus usos.
CA2356542A1 (en) 1998-12-23 2000-07-06 Human Genome Sciences, Inc. Peptidoglycan recognition proteins
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
AU5625500A (en) 1999-06-18 2001-01-09 Emory University Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin
US6964854B1 (en) 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
US6376654B1 (en) 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001016183A1 (en) 1999-08-30 2001-03-08 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
US6319675B1 (en) 1999-11-24 2001-11-20 Millennium Pharmaceuticals, Inc. Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
US6835549B2 (en) 2000-02-24 2004-12-28 University Of Medicine & Dentistry Of New Jersey Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
AU2001270942A1 (en) 2000-05-11 2001-11-20 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
WO2002010764A2 (en) 2000-07-31 2002-02-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
AU9648301A (en) 2000-10-02 2002-04-15 Oklahoma Med Res Found Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
US6743898B2 (en) 2001-03-15 2004-06-01 Ochsner Clinic Foundation Monoclonal antibodies that suppress B cell growth and/or differentiation
EP1372741B1 (en) 2001-03-30 2006-08-09 University of Massachusetts Morpholino imaging and therapy
US6824778B2 (en) 2001-04-23 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Prophylactic and therapeutic monoclonal antibodies
AU2002303832A1 (en) 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
US7049060B2 (en) 2001-11-05 2006-05-23 Ortho-Clinical Diagnostics, Inc. HCV anti-core monoclonal antibodies
US6630016B2 (en) * 2002-01-31 2003-10-07 Koslow Technologies Corp. Microporous filter media, filtration systems containing same, and methods of making and using
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
ATE477276T1 (de) 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2003106497A1 (en) 2002-06-14 2003-12-24 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
JP2006517963A (ja) 2003-01-28 2006-08-03 シェーリング　コーポレイション 形質細胞様樹状細胞についての抗体特異性
JP4874090B2 (ja) 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
JP4937751B2 (ja) 2003-06-13 2012-05-23 イミューノメディクス、インコーポレイテッド Ｄ−アミノ酸ペプチド
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
WO2005070026A2 (en) * 2004-01-23 2005-08-04 Seattle Genetics, Inc. Drug immunoconjugate combination therapy
AU2005214361B2 (en) 2004-02-13 2011-03-24 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
WO2006094192A2 (en) 2005-03-03 2006-09-08 Immunomedics, Inc. Humanized l243 antibodies
AU2006232920B2 (en) 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
CN101534865A (zh) 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
MX2009006466A (es) * 2006-12-13 2009-06-26 Schering Corp Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
US8267865B2 (en) 2007-02-16 2012-09-18 University Of Rochester Sonoelastographic shear velocity imaging using crawling wave excitation
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
JP2013531068A (ja) * 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2015012904A2 (en) * 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN104837508A (zh) * 2012-12-13 2015-08-12 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
US9492566B2 (en) * 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2014124227A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
CN109310385A (zh) * 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效

Similar Documents

Publication Publication Date Title
JP2017536340A5 (cg-RX-API-DMAC7.html)
Bhatt et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status
BR112019010356A2 (pt) molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
JP2019501204A5 (cg-RX-API-DMAC7.html)
JP2017506264A5 (cg-RX-API-DMAC7.html)
Shi et al. The dual roles of A20 in cancer
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2018508512A5 (cg-RX-API-DMAC7.html)
JP2015534577A5 (cg-RX-API-DMAC7.html)
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
JP2016502504A5 (cg-RX-API-DMAC7.html)
HRP20160190T1 (hr) Protutijela anti-igf
MX393934B (es) Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes
JP2018070648A5 (cg-RX-API-DMAC7.html)
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
JP2016538344A5 (cg-RX-API-DMAC7.html)
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
RU2016132759A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
JP2015528491A5 (cg-RX-API-DMAC7.html)
RU2016132635A (ru) Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
WO2016022939A8 (en) Human monoclonal antibodies specific for 5t4 and methods of their use